98 related articles for article (PubMed ID: 21156243)
1. Correlation between clinical characteristics, survival and genetic alterations in patients with hepatocellular carcinoma from Saudi Arabia.
Al-Qahtani A; Al-Hazzani T; Al-hussain T; Al-Ghamdi A; Al-Mana H; Al-Arifi S; Al-Ahdal M; Aly M
Cancer Genet Cytogenet; 2010 Dec; 203(2):269-77. PubMed ID: 21156243
[TBL] [Abstract][Full Text] [Related]
2. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
[TBL] [Abstract][Full Text] [Related]
3. Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma.
Huang TJ; Huang BJ; Liang QW; Huang CW; Fang Y
Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):62-8. PubMed ID: 14969840
[TBL] [Abstract][Full Text] [Related]
4. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
5. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients.
Berns EM; Klijn JG; Smid M; van Staveren IL; Look MP; van Putten WL; Foekens JA
Genes Chromosomes Cancer; 1996 Jul; 16(3):170-9. PubMed ID: 8814449
[TBL] [Abstract][Full Text] [Related]
6. c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis.
Abou-Elella A; Gramlich T; Fritsch C; Gansler T
Mod Pathol; 1996 Feb; 9(2):95-8. PubMed ID: 8657726
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray.
Wang Y; Wu MC; Sham JS; Zhang W; Wu WQ; Guan XY
Cancer; 2002 Dec; 95(11):2346-52. PubMed ID: 12436441
[TBL] [Abstract][Full Text] [Related]
8. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
9. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization.
Kubokura H; Tenjin T; Akiyama H; Koizumi K; Nishimura H; Yamamoto M; Tanaka S
Ann Thorac Cardiovasc Surg; 2001 Aug; 7(4):197-203. PubMed ID: 11578259
[TBL] [Abstract][Full Text] [Related]
10. [Quantitative detection of HER-2 oncogene amplification in primary hepatocellular carcinoma using dual FISH technique and its clinical significance].
Huang BJ; Huang TJ; Liang QW; Huang CW; Fang Y
Yi Chuan Xue Bao; 2001; 28(9):793-800. PubMed ID: 11582736
[TBL] [Abstract][Full Text] [Related]
11. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma.
Chan KL; Guan XY; Ng IO
Hum Pathol; 2004 Nov; 35(11):1324-31. PubMed ID: 15668888
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of c-myc gene without gene amplification in human hepatocellular carcinoma.
Wu B; Wang M; You W; Yang S
Chin Med J (Engl); 1996 Dec; 109(12):922-5. PubMed ID: 9275322
[TBL] [Abstract][Full Text] [Related]
13. Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma.
Ooi A; Suzuki S; Nakazawa K; Itakura J; Imoto I; Nakamura H; Dobashi Y
Anticancer Res; 2009 Jan; 29(1):19-26. PubMed ID: 19331129
[TBL] [Abstract][Full Text] [Related]
14. [Correlation between hypomethylation of c-myc and c-N-ras oncogenes and pathological changes in human hepatocellular carcinoma].
Shen L; Qui D; Fang J
Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):173-6. PubMed ID: 10920889
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer.
Williams JA; Wang ZR; Parrish RS; Hazlett LJ; Smith ST; Young SR
Exp Mol Pathol; 1999 Dec; 67(3):135-43. PubMed ID: 10600396
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES
Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the TP53 gene in human gliomas.
Rasheed BK; McLendon RE; Herndon JE; Friedman HS; Friedman AH; Bigner DD; Bigner SH
Cancer Res; 1994 Mar; 54(5):1324-30. PubMed ID: 8118823
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of c-myc gene amplification, MTS1/p16 gene alternation, and HBV infection in human hepatocellular carcinoma].
Zhang J; Wang K; Cong S; Qiu F; Wang X; Wang P
Zhonghua Gan Zang Bing Za Zhi; 2001 Oct; 9(5):294-6. PubMed ID: 11676877
[TBL] [Abstract][Full Text] [Related]
19. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
Jenkins RB; Qian J; Lieber MM; Bostwick DG
Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
[TBL] [Abstract][Full Text] [Related]
20. Abnormal expression of pan-ras, c-myc and tp53 in squamous cell carcinoma of cervix: correlation with HPV and prognosis.
Ngan HY; Cheung AN; Liu SS; Cheng DK; Ng TY; Wong LC
Oncol Rep; 2001; 8(3):557-61. PubMed ID: 11295080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
